Abstract:Abstract Objectives Gastrointestinal hormones contribute to the beneficial effects of Roux-en-Y gastric bypass surgery (RYGB) on glycemic control. Secretin is secreted from duodenal S cells in response to low luminal pH, but it is unknown whether its secretion is altered after RYGB and if secretin contributes to the postoperative improvement in glycemic control. We hypothesized that secretin secretion increases after RYGB as a result of the diversion of nutrients to more distal parts of the small intestine, and thereby affects islet hormone release. Methods A specific secretin radioimmunoassay was developed, evaluated biochemically, and used to quantify plasma concentrations of secretin in 13 obese individuals before, 1 week after, and 3 months after RYGB. Distribution of secretin and its receptor was assessed by RNA sequencing, mass-spectrometry and in situ hybridization in human and rat tissues. Isolated, perfused rat intestine and pancreas were used to explore the molecular mechanism underlying glucose-induced secretin secretion and to study direct effects of secretin on glucagon, insulin, and somatostatin secretion. Secretin was administered alone or in combination with GLP-1 to non-sedated rats to evaluate effects on glucose regulation. Results Plasma postprandial secretin was more than doubled in humans after RYGB ( P < 0.001). The distal small intestine harbored secretin expressing cells in both rats and humans. Glucose increased the secretion of secretin in a sodium-glucose cotransporter dependent manner when administered to the distal part but not into the proximal part of the rat small intestine. Secretin stimulated somatostatin secretion (fold change: 1.59, P < 0.05) from the perfused rat pancreas but affected neither insulin ( P = 0.2) nor glucagon ( P = 0.97) secretion. When administered to rats in vivo, insulin secretion was attenuated and glucagon secretion increased ( P = 0.04), while blood glucose peak time was delayed (from 15 to 45 min) and gastric emptying time prolonged ( P = 0.004). Conclusions Glucose-sensing secretin cells located in the distal part of the small intestine may contribute to increased plasma concentrations observed after RYGB. The metabolic role of the distal S cells warrants further studies.

Is glucose‐induced hypersecretion of glicentin after the revision surgery using Roux‐en‐Y gastric bypass related to improved glycemic control due to insulin hypersecretion in a type 2 diabetes patient without diabetes remission after laparoscopic sleeve gastrectomy?

Efficacy of laparoscopic sleeve gastrectomy on morbidly obese patients with type 2 diabetes mellitus]

Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.

Risk Factors for Relapse of Hyperglycemia after Laparoscopic Roux-en-Y Gastric Bypass in T2DM Obese Patients: a 5-Year Follow-Up of 24 Cases

Insulin Resistance Remission Following Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy in Chinese Type 2 Diabetes Mellitus Patients with a Body Mass Index of 27.5–32.5 Kg/m2

Contribution of Endogenous Glucagon-Like Peptide-1 to Changes in Glucose Metabolism and Islet Function in People with Type 2 Diabetes Four Weeks after Roux-en-Y Gastric Bypass (RYGB).

Changes of blood glucose and gastrointestinal hormones 4 months after Roux-en-Y gastric bypass surgery in Chinese obese type 2 diabetes patients with lower body mass index.

Secretin release after Roux-en-Y Gastric Bypass reveals a population of glucose-sensitive S-cells in distal small intestine

Changes of Blood Glucose and Gastrointestinal Hormones 4 Months after Roux‐en‐Y Gastric Bypass Surgery in Chinese Obese Type 2 Diabetes Patients with Lower Body Mass Index

Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine

An analysis of islet function in patients with type 2 diabetes mellitus after laparoscopic Roux-en-Y gastric bypass surgery

Evaluation of Insulin Resistance Improvement after Laparoscopic Sleeve Gastrectomy or Gastric Bypass Surgery with HOMA-IR.

RNA sequencing unravels novel L cell constituents and mechanisms of GLP-1 secretion in human gastric bypass-operated intestine

Effect of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy on Fasting Gastrointestinal and Pancreatic Peptide Hormones: A Prospective Nonrandomized Trial.

Metabolomics Study of Roux-En-Y Gastric Bypass Surgery (rygb) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography-Mass Spectrometry

Roux-en-Y Gastric Bypass-Induced Improvement of Glucose Tolerance and Insulin Resistance in Type 2 Diabetic Rats Are Mediated by Glucagon-Like Peptide-1

Curative effects of LRYGB and LSG on T2DM and their influences on GLP-1 and Ghrelin

Predictive Value of Gut Peptides in T2D Remission: Randomized Controlled Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy and Greater Curvature Plication

A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass

Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery

Upregulation of IRS-1 expression in Goto-Kakizaki rats following Roux-en-Y gastric bypass surgery: resolution of type 2 diabetes?